Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- AstraZeneca Japan Taps Ex-Takeda Japan Oncology Head as New Chief
July 4, 2022
- Fujifilm to Inject US$1.6 Billion to Rev Up Biopharma CDMO Biz
July 1, 2022
- Mitsubishi Tanabe Seeks Congenital CMV Nod for Valixa Dry Syrup
July 1, 2022
- AbbVie Japan Files Skyrizi for Palmoplantar Pustulosis
July 1, 2022
- Blood Cancer Drug Pegaspargase Filed in Japan: Nihon Servier
July 1, 2022
- Sanofi Seeks Dupixent Label Expansion for Prurigo Nodularis in Japan
July 1, 2022
- 37 Pharma Execs Get 100 Million-Plus Yen in FY2021, Top 3 at Takeda: Securities Reports
July 1, 2022
- Despite 4 Trillion Yen Debt, Takeda CEO Confident in Deleveraging, Pipeline Boost, Shareholder Returns
June 30, 2022
- Pfizer Seeks Japan Approval of Aplastic Anemia Med
June 30, 2022
- Tissue-Engineering Market in Asia to Hit 712 Billion Yen in 2030: Fuji Keizai
June 30, 2022
- Takeda CEO’s Pay Down to 1.86 Billion Yen in FY2021
June 30, 2022
- Wholesalers Bear Over 50 Billion Yen in Annual Costs Tied to Restricted Drug Supply: Crecon Estimate
June 29, 2022
- Astellas/Sutro to Codevelop Next-Gen Immunostimulatory ADCs for Cold Tumors
June 29, 2022
- Solasia, Nippon Kayaku Forge Capital and Business Tie-Up
June 29, 2022
- Ono Expands CAR-T Collaboration with Fate Therapeutics
June 29, 2022
- Shingrix Filed in Japan for At-Risk Adults aged 18 and Older: GSK
June 29, 2022
- Brexpiprazole Cuts Alzheimer’s Agitation in PIII Study: Otsuka/Lundbeck
June 28, 2022
- Astellas’ Pompe Gene Therapy Trial Hit with FDA Clinical Hold
June 28, 2022
- Enhertu Filed for HER2 Low Breast Cancer in Japan: Daiichi Sankyo
June 28, 2022
- Novo Japan Seeks Thumbs-Up for Sogroya Use in Short Stature
June 28, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…